Redwood AI’s stock capped a turbulent week with a 17.78% five-day decline, landing at C$3.70 on the Canadian Securities Exchange and wiping out more than half the company’s value since January. The selling pressure, punctuated by an intraday swing from C$2.33 to C$4.40 on Friday alone, reflects deep investor scepticism toward two high-profile announcements squeezed into the same seven-day window.
The more consequential news dropped on 28 May: a non-binding letter of intent to acquire Quantum.IQ, a Vancouver-based post-quantum cryptography specialist. Under the all-share framework, Redwood would issue up to 7 million shares upfront and another 7 million if the target hits certain milestones — a total potential dilution of 14 million shares. Those shares come with staggered lock-ups: 10% released after four months, 15% after six, and the remaining 75% parcelled out over one to two years. The deal, which requires approval from the Canadian Securities Exchange and faces a host of conditions — including satisfactory due diligence, regulatory clearances, and key-person dependencies — is far from a done deal.
Just five days earlier, on 22 May, Redwood had announced a partnership with Resilience Biosciences to build AI-driven workflows for small-molecule drug discovery, covering synthetic route planning and patentability analysis. Taken together, the two moves thrust the company into hot-button sectors — quantum-safe cybersecurity and AI-augmented pharma R&D — but the market response was unmistakably cold.
Should investors sell immediately? Or is it worth buying Redwood AI?
Investors appear to be punishing the all-stock structure of the Quantum.IQ bid, which offers no cash component and leaves existing shareholders exposed to prolonged dilution without any guarantee of a definitive agreement. The risks laid out by Redwood itself — including the early stage of quantum technology, reliance on key personnel, and potential due diligence findings — only amplify the caution. No analyst has yet published a formal rating on the stock, leaving the narrative in the hands of a market that wants to see binding contracts and measurable outcomes, not letters of intent.
Between the drug discovery collaboration and the quantum security gambit, Redwood has staked out two ambitious technological frontiers in a single week. Whether either initiative matures into a binding deal or a revenue-generating partnership will be determined in the coming weeks of due diligence. For now, the stock’s trajectory suggests investors are betting the odds of success remain long.
Ad
Redwood AI Stock: Buy or Sell?! New Redwood AI Analysis from May 30 delivers the answer:
The latest Redwood AI figures speak for themselves: Urgent action needed for Redwood AI investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from May 30.
Redwood AI: Buy or sell? Read more here...
